Aurobindo Pharma. File
| Photo Credit: Special Arrangement
Aurobindo Pharma subsidiary Auro Pharma is acquiring the non-oncology prescription formulations business of Khandelwal Laboratories on a going concern basis, on slump sale basis.
It is for a cash consideration of ₹325 crore subject to true-up adjustments for the working capital as provided for in the definitive agreements. There are 23 brands marketed in 67 SKUs and 9 pipeline products in the business where anti-infective as well as pain management are major portfolios, Aurobindo Pharma said in a filing on Thursday.
The business generated a turnover of ₹113.5 crore in 2024-25 with an EBITDA of ₹28.9 crore. It has around 470 people strong field force and more than 1,600 stockists and other distribution related infrastructure.
The acquisition, effective January 1, 2026, will add further brands in pain management and anti-infective, complement the existing product portfolios and help expand business in domestic market, it said.
Published – January 01, 2026 07:54 pm IST
